Interleukin-2 (IL-2), a potent T-cell-stimulating cytokine, was the first U.S. Food and Drug Administration (FDA)-approved immunotherapeutic with considerable treatment effects in metastatic melanoma and renal cell carcinoma (RCC) patients1–3. The gene discussed is IL2; the disease is metastatic melanoma.